Systemic Lupus Erythematosus Therapeutics Analysis 2019- PharmaProff

Systemic Lupus Erythematosus Therapeutics Analysis 2019- PharmaProff
Press Release

Systemic lupus erythematosus therapeutics currently exhibits a proliferating pipeline with 15+ therapeutic candidates.

Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation of cartilage and blood vessels. Pain and swelling in joints, sensitivity to sun, unexplained fever, joints and muscle pain, mouth ulcers, swollen glands, and others are some common symptoms of the disease. Additionally, kidneys, lungs, heart, and others can also get affected by SLE. The diagnosis of SLE is little difficult as it requires multiple tests and constant analysis. Anticardiolipin antibody test, antinuclear antibody (ANA) test, blood chemistries, complete blood count (CBC), urinalysis, and the erythrocyte sedimentation rate (ESR) are some tests to diagnose the disease.

Request for report sample at: https://www.pharmaproff.com/request-sample/1258

According to the research, most of the drug candidates being developed for SLE are administered topically. It is observed that this route of medication is most effective method of treatment. It has been found that topical route of administration is easy to use, non-invasive, and ensures high level of patient satisfaction.

Pharmaceutical companies are tending to develop various strategies to enhance the therapeutic pipeline of SLE. For instance, Ablynx is developing vobarilizumab for the treatment of vobarilizumab with the help of its proprietary Nanobody technology.

Takeda Pharmaceutical Company Limited, Anthera Pharmaceuticals Inc., Genentech Inc., UCB Biopharma SPRL, Merck & Co. Inc., Ablynx, and GlaxoSmithKline plc are some of the prominent players for developing drugs and therapies for SLE.

SLE Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

This post was originally published on Pharmaceutical Industry